{
    "clinical_study": {
        "@rank": "114233", 
        "arm_group": [
            {
                "arm_group_label": "ABX Combined With Cisplatin", 
                "arm_group_type": "Experimental", 
                "description": "ABX\uff0c100mg/m2\uff0cd1\u30018\u300115\uff0civgtt,in 30 min\uff0c28day one cycle\uff1b cisplin 75mg/m2 d1 ivgtt"
            }, 
            {
                "arm_group_label": "Gemcitabine Combined With Cisplatin", 
                "arm_group_type": "Active Comparator", 
                "description": "gemcitabine 1000mg/m2\uff0cd1\u30018\uff1bcisplatin 75mg/m2 d1 ivgtt,3 weeks one cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "Assess the PFS/ORR/OS of  ABX Combined With Cisplatin Compared With Gemcitabine Combined\n      With Cisplatin in first Treatment of NSCLC"
        }, 
        "brief_title": "ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1.18~75 years 2.Patients who were diagnosed by the histologic, cytologic diagnosis of\n        IIIb-IV non-small cell lung cancer 3.Presence of at least one index lesion measurable by\n        CT scan or MRI 4.Ecog0-1 5.Expected life time longer than 12 weeks 6.Normal laboratory\n        values:\n\n          -  leucocyte \u2265 4\u00d7109/L\n\n          -  neutrophil \u2265 1.5\u00d7109/L\n\n          -  platelet \u2265 100\u00d7109/L\n\n          -  Hemoglobin \u2265 10g/L\n\n          -  ALT and\n\n          -  AST \u2264 2.5\u00d7ULN (\u2264 5\u00d7ULN if liver metastasis) 7.Signed written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients have used drugs according to protocol\n\n          -  Patients were allergic to pemetrexed or cisplatin\n\n          -  Patients received radiotherapy or other biological treatment 4 weeks before the trial\n\n          -  Uncontrolled hydrothorax or hydropericardium\n\n          -  neuropathy toxicity \u2265 CTC 3\n\n          -  Severe symptomatic heart disease\n\n          -  Active upper gastrointestinal ulcer or digestive disfunction\n\n          -  Severe infection or metabolic disfunction\n\n          -  Patients with other malignant tumor\n\n          -  Uncontrolled brain metastases\n\n          -  Patients have accepted other clinical trials\n\n          -  Female patients during their pregnant and lactation period, or patients without\n             contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810367", 
            "org_study_id": "ABX-CJH"
        }, 
        "intervention": [
            {
                "arm_group_label": "ABX Combined With Cisplatin", 
                "intervention_name": "ABX Combined With Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gemcitabine Combined With Cisplatin", 
                "intervention_name": "Gemcitabine Combined With Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "PFS", 
        "lastchanged_date": "March 12, 2013", 
        "location": {
            "contact": {
                "email": "changjianhua@163.com", 
                "last_name": "Chang jian hua, MD,PHD", 
                "phone": "64175590", 
                "phone_ext": "8217"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Cancer hospital Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in First Line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Stage II Randomized Controlled Trials", 
        "overall_contact": {
            "email": "changjianhua@163.com", 
            "last_name": "CHANG JIAN HUA, MD,PHD", 
            "phone": "64175590", 
            "phone_ext": "8907"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PFS", 
            "safety_issue": "No", 
            "time_frame": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810367"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Chang Jian Hua", 
            "investigator_title": "Vice director of department of chemotherapy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}